Lumos Pharma Inc (LUMO)
4.32
+0.02
(+0.47%)
USD |
NASDAQ |
Nov 14, 16:00
4.32
0.00 (0.00%)
After-Hours: 17:55
Lumos Pharma Net Income (Quarterly): -7.551M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -7.551M |
| March 31, 2024 | -10.44M |
| December 31, 2023 | -9.457M |
| September 30, 2023 | -8.30M |
| June 30, 2023 | -8.931M |
| March 31, 2023 | -7.346M |
| December 31, 2022 | -8.247M |
| September 30, 2022 | -7.251M |
| June 30, 2022 | -15.56M |
| March 31, 2022 | -7.72M |
| December 31, 2021 | -5.641M |
| September 30, 2021 | -7.488M |
| June 30, 2021 | -8.67M |
| March 31, 2021 | -8.631M |
| December 31, 2020 | -2.415M |
| September 30, 2020 | 1.765M |
| June 30, 2020 | -5.353M |
| March 31, 2020 | 0.34M |
| December 31, 2019 | -2.362M |
| September 30, 2019 | -2.669M |
| June 30, 2019 | -2.569M |
| March 31, 2019 | -2.105M |
| December 31, 2018 | -10.57M |
| September 30, 2018 | -7.403M |
| June 30, 2018 | -17.31M |
| Date | Value |
|---|---|
| March 31, 2018 | -18.31M |
| December 31, 2017 | -13.69M |
| September 30, 2017 | -20.63M |
| June 30, 2017 | -16.73M |
| March 31, 2017 | -20.91M |
| December 31, 2016 | -13.51M |
| September 30, 2016 | -15.54M |
| June 30, 2016 | -32.39M |
| March 31, 2016 | -23.72M |
| December 31, 2015 | -21.57M |
| September 30, 2015 | -15.91M |
| June 30, 2015 | -14.09M |
| March 31, 2015 | 11.19M |
| December 31, 2014 | 120.01M |
| September 30, 2014 | -5.598M |
| June 30, 2014 | -9.164M |
| March 31, 2014 | -9.236M |
| December 31, 2013 | -8.046M |
| September 30, 2013 | -8.123M |
| June 30, 2013 | -7.077M |
| March 31, 2013 | -7.934M |
| December 31, 2012 | -6.319M |
| September 30, 2012 | -5.851M |
| June 30, 2012 | -6.309M |
| March 31, 2012 | -4.842M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-15.56M
Minimum
Jun 2022
1.765M
Maximum
Sep 2020
-6.803M
Average
-7.551M
Median
Jun 2024
Net Income (Quarterly) Benchmarks
| Boston Scientific Corp | 468.00M |
| Calidi Biotherapeutics Inc | -5.767M |
| NovaBay Pharmaceuticals Inc | -1.585M |
| Palatin Technologies Inc | -8.250M |
| iBio Inc | -7.778M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.488M |
| Total Expenses (Quarterly) | 8.311M |
| EPS Diluted (Quarterly) | -0.93 |
| Enterprise Value | 18.13M |
| Profit Margin (Quarterly) | -1.55K% |
| Earnings Yield | -102.5% |
| Normalized Earnings Yield | -102.55 |